Skip to main content
HEM Pharma Inc. logo

HEM Pharma Inc. — Investor Relations & Filings

Ticker · 376270 ISIN · KR7376270005 KO Manufacturing
Open in API
Filings indexed 93 across all filing types
Latest filing 2024-03-29 Audit Report / Informat…
Country KR South Korea
Listing KO 376270

About HEM Pharma Inc.

https://hempharma.bio/

HEM Pharma Inc. is a biotechnology company specializing in microbiome-based healthcare solutions. The company researches and develops Live Biotherapeutic Products (LBPs), health functional foods, and other bio-products derived from human-effective microbes. A core component of its R&D is the proprietary Pharmaceutical Meta-Analysis System (PMAS), a technology platform that simulates the human gut microbiome to screen for and analyze beneficial microorganisms. In addition to its product pipeline, HEM Pharma provides personalized healthcare services based on microbiome analysis and offers Contract Development and Manufacturing Organization (CDMO) services for next-generation biological materials.

Recent filings

Filing Released Lang Actions
사업보고서 (2023.12)
Audit Report / Information Classification · 1% confidence The document is a comprehensive 'Audit Report' (감사보고서) for the company 'HEM Pharma' (주식회사 에이치이엠파마) for the fiscal year ending December 31, 2023. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This is a full financial audit report, not an earnings release or a summary, and it is not an annual report (10-K) in the sense of a narrative business report, but rather the formal audit document. FY 2023
2024-03-29 Korean
[기재정정]분기보고서 (2023.09)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for HEM Pharma, which includes detailed financial statements (Balance Sheet, Income Statement, Cash Flow, etc.) for the third quarter of 2023. It is a formal regulatory filing submitted to the Financial Services Commission and the Korea Exchange. Although it is labeled as a 'correction' (정정신고), it contains the full substantive financial data and analysis required for an interim/quarterly report, thus fitting the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-12-15 Korean
[첨부추가]분기보고서 (2023.09)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the 3rd quarter of 2023, filed by HEM Pharma Inc. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-14 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matters Report' (주요사항보고서) from a South Korean company, HEM Pharma, detailing a decision for a third-party capital increase (유상증자결정). This document outlines the specifics of the share issuance, the purpose of the funds, the third-party allocation details, and the legal basis for the issuance. In the context of Korean corporate filings, this is a regulatory disclosure regarding capital changes, which falls under the 'Share Issue/Capital Change' category.
2023-11-08 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '주식회사 에이치이엠파마' (HEM Pharma Inc.) covering the period from January 1, 2023, to June 30, 2023. It contains comprehensive financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-31 Korean
[기재정정]주요사항보고서(유형자산양도결정)
M&A Activity Classification · 1% confidence The document is a 'Major Report' (주요사항보고서) filed with the Financial Services Commission (금융위원회) in South Korea. It specifically details a 'Decision to Transfer Tangible Assets' (유형자산 양도 결정) and is a correction filing (정정신고) of a previous report. In the context of Korean regulatory filings (DART system), these are categorized as general regulatory announcements that do not fit into specific financial reporting categories like 10-K or IR, thus falling under the RNS (Regulatory Filings) category.
2023-05-30 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.